Navigation Links
Photophobia in Medical News

MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints

... 33.8 percent for placebo (p<0.0001); photophobia free: 46.6 percent of patients who received ... include pain relief, and being phonophobia, photophobia and nausea free at two hours after dosing. ... include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia ...

MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine

... endpoints will be pain relief at two hours, and freedom from nausea, photophobia and phonophobia at two hours. About MAP0004 MAP0004 is a proprietary ... 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research ...

Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference

... to treat cystinosis can cause serious health consequences, including renal failure (and resultant kidney transplant), growth failure, rickets, photophobia and blindness. Cystinosis is typically treated with an immediate-release form of cysteamine bitartrate, which is currently the only therapeutic ...

MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results

... at 24 hours in a treatment received population. The trial also showed clinically significant trends in the resolution of phonophobia, photophobia and nausea at certain time points. MAP0004 was shown in the trial to be well tolerated and no serious adverse events were reported. -- ...

ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)

... Drug Administration (FDA) for Xibrom(TM) QD (once-daily). The Company is seeking approval for Xibrom QD as a treatment for inflammation, pain, and photophobia following cataract surgery. Xibrom(TM) (bromfenac ophthalmic solution) Xibrom is a topical non-steroidal anti-inflammatory compound for ...

Combination Therapy More Effective Than Monotherapy for Treating Migraine

... than placebo for headache relief at two hours after dosing (study 1, 65 percent vs. 28 percent; and study 2, 57 percent vs. 29 percent;), absence of photophobia (sensitivity to light) at two hours (58 percent vs. 26 percent; and 50 percent vs. 32 percent;), and absence of phonophobia (sensitivity to sound) at ...
Photophobia in Medical Technology

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

... 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine. This ... primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. MAP will also ...

TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache

... relief of migraine-associated symptoms such as nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound), as well as ... pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia. About AK Receptor Antagonists AMPA/kainate (AK) ...

ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%

... efficacy. In addition, both Phase III studies showed highly statistically significant results in the proportion of subjects with no photophobia (light sensitivity) at every study visit post-cataract surgery. This is in concordance with previous clinical trials with Xibrom. The studies also ...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... of the condition is anterior uveitis, associated primarily with inflammation of the iris. If left untreated, uveitis can cause debilitating pain and photophobia as well as permanent damage and vision loss due to the development of glaucoma, cataract or retinal edema. Dr. Kaufman's poster, "Data from Trials ...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

... relief in as fast as ten minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine. The therapeutic agent in MAP0004 is dihydroergotamine (DHE), which has a long ...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

... ten minutes of dosing, and this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast ...

TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel

... traditionally required for regulatory approval. These endpoints included pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia. About AK Receptor Antagonists AK receptors are part of the glutamate biological pathway that transmits pain signals to the brain. ...

Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA

... versus placebo on the following variables: -- Headache relief -- Absence of phonophobia (sensitivity to sound) -- Absence of photophobia (sensitivity to light) -- Absence of nausea The second objective was to assess the sustained effect of Trexima from two through 24 hours ...
Photophobia in Medical Definition

Pathology

... Aniseikonia Visual disturbances and blindness Amblyopia - Leber's congenital amaurosis - Subjective ( Asthenopia , Hemeralopia , photophobia , Scintillating scotoma ) - Diplopia - Scotoma - Anopsia ( Binasal hemianopsia , Bitemporal hemianopsia , Homonymous hemianopsia , ...
Photophobia in Medical Dictionary

Photophobia

... photophobia : Painful oversensitivity to light. For example, there is photophobia in measles ( rubeola ). Keeping the lights dim ... may be useful. Sunglasses may also help. photophobia ; Light sensitivity; Light hurts the eyes ; ...

Eye pain

... Guide > Eye Pain Eye Pain - ... Eye pain . Sensitivity to light ( photophobia ). Decreased vision in all or part of the vision field. Blurred ... there a fever ? Is there a stiff neck? Are the eyes light-sensitive ( photophobia )? Is there eye pain ? Is there loss of vision ? ...

Nystagmus

... sign of the syndrome in infancy is often extreme light sensitivity ( photophobia ) and a wobbling of the eyes ( nystagmus ). From 4 to 10% of ... nystagmus (recurrent flickering back-and-forth eye movements ), photophobia , amaurosis, color blindness , ... Nystagmus (rhythmic jerking ...

Eye movements

... Los Angeles, CA. Review provided by VeriMed Healthcare Network. Rapid eye movements ( nystagmus ) Strabismus ( eyes not tracking properly) photophobia (avoidance of light because of discomfort) Decreased visual acuity or even functional blindness ... The involuntary eye movements of ...

Tearing

... syndrome . But these are called irritant tears, and are produced as a reflex reaction to the syndrome . excessive tearing light sensitivity ( photophobia ) closure of one or both eyes in the light cloudy, enlarged cornea one eye may be larger than the other vision loss ... - Tearing - ...
Photophobia in Biological Technology

Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA

... damage and vision loss due to the development of glaucoma, cataract, or retinal edema. In addition to potential vision loss, the severe pain and photophobia that accompany anterior uveitis can be debilitating. About Durezol Durezol (difluprednate ophthalmic emulsion) 0.05% is a topical ...

MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine

... safety and efficacy of MAP0004 as a potential acute treatment for migraine. The primary efficacy endpoints are pain relief and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. The study is also evaluating earliest onset of pain relief, pain relief at 10 minutes, ...

Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008

... Failure to treat the disease can cause serious health consequences, including renal failure and resultant kidney transplant, growth failure, rickets, photophobia and blindness. In collaboration with the University of California, San Diego ("UCSD"), supported by the Cystinosis Research Foundation ("CRF"), ...

ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results

... December of 2007 after announcing, earlier in the year, positive Phase III results for Xibrom QD as a treatment for inflammation, pain, and photophobia following cataract surgery -- Announced statistically significant Phase II/III study results for Bepreve in treating ocular itching and ...
Photophobia in Biological Definition

Albinism

... that often come with age, the gain is generally thought be out-weighed by the trauma. The lack of pigment in the eye generally leads to ocular photophobia or hyper-photo-sensitivity . This is due not so much by the iris allowing stray light into enter the eye, as to a lack of pigment within the eye, ...
Other Contents
(Date:9/17/2014)... Kathleen Doheny HealthDay Reporter ... major food and beverage companies have made good on their ... report finds. The companies, acting together through the Healthy ... the market between 2007 and 2012 and 1.5 trillion by ... "The 16 companies collectively met their pledge and exceeded their ...
(Date:9/17/2014)... at Moffitt Cancer Center, including Center Director Thomas A. Sellers, ... discovered 23 new regions of the genome that influence the ... Sept. 14 in Nature Genetics . , Prostate cancer ... 1 in 6 men will be diagnosed with the disease ... A man with one close relative, a brother or father ...
(Date:9/17/2014)... facial paralysis are perceived as being less happy simply ... facial expression, a new study from an Oregon State ... the important role the face plays in everyday communication ... with facial paralysis because of their disability, said Kathleen ... of Liberal Arts at Oregon State University. , "People ...
(Date:9/17/2014)... 2014 Tools4ever, the market ... solutions and Boston Software Systems, leader in ... relationship. Under the agreement, Tools4ever will ... functionality within its identity and password management ... healthcare automation platforms that streamline complex processes ...
(Date:9/17/2014)... Kessler Foundation is the recipient of one of ... Multiple Sclerosis (MS) Alliance. Nancy Chiaravalloti, PhD, ... Research, is principal investigator of the study, which ... in individuals with progressive multiple sclerosis. The Foundation ... the Alliance to investigators in nine countries, with ...
Breaking Medicine News(10 mins):Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2
(Date:9/17/2014)... bags and their environmental impact recently scored a major ... ban on the bags, and Governor Jerry Brown is ... is not yielding without a fight, according to an ... weekly newsmagazine of the American Chemical Society. , Alexander ... anti-bag campaign logged its first small victory in 1990 ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... Informatics at IMIM (Hospital del Mar Medical Research Institute) ... recently published a study in eLife showing ... in the evolution of new proteins, some of which ... Ribosomes produce proteins from the instructions found in an ... is RNA containing information for the synthesis of proteins, ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
Other TagsOther Tags